Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03311828 · ClinicalTrials.gov registry record · Phase 1
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03311828 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 12 participants.
The verdict
NCT03311828, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This pilot phase I clinical trial studies how well copper 64Cu-DOTA-daratumumab positron emission tomography works in diagnosing patients with multiple myeloma that has come back. Diagnostic procedures, such as copper 64Cu-DOTA-daratumumab positron emission tomography, may help evaluate the extent of multiple myeloma in patients prior to the initiation of treatment and ultimately monitor disease status/response during and post treatment.
Interventions
- PROCEDURE Positron Emission Tomography
- DRUG Imaging Agent
- BIOLOGICAL Daratumumab
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-02-21 |
| Est. Completion | 2023-06-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03311828
The ClinicalTrials.gov registry entry for NCT03311828 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Positron Emission Tomography is the first listed.
NCT03311828 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03311828 about?
NCT03311828 is a clinical study titled "Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma". This pilot phase I clinical trial studies how well copper 64Cu-DOTA-daratumumab positron emission tomography works in diagnosing patients with multiple myeloma that has come back. Diagnostic procedures, such as copper 64Cu-DOTA-daratumumab positron emission tomography, may help evaluate the extent o...
What is the current status of trial NCT03311828?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-02-21. Estimated completion is 2023-06-05.
What interventions are being tested in trial NCT03311828?
The interventions under investigation include: Positron Emission Tomography (PROCEDURE), Imaging Agent (DRUG), Daratumumab (BIOLOGICAL), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT03311828?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.